The Potential Role of Genetically-Modified Pig Mesenchymal Stromal Cells in Xenotransplantation

被引:0
|
作者
Jiang Li
Mohamed B. Ezzelarab
David Ayares
David K. C. Cooper
机构
[1] University of Pittsburgh Medical Center,The Thomas E. Starzl Transplantation Institute
[2] Tianjin First Central Hospital,Department of Transplantation Surgery
[3] Tianjin Medical University,undefined
[4] Revivicor Inc.,undefined
来源
Stem Cell Reviews and Reports | 2014年 / 10卷
关键词
Mesenchymal stromal cells; Pig; Xenotransplantation;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stromal cells (MSCs) are known to have regenerative, anti-inflammatory, and immunodulatory effects. There are extensive indications that pig MSCs function satisfactorily across species barriers. Pig MSCs might have considerable therapeutic potential, particularly in xenotransplantation, where they have several potential advantages. (i) pMSCs can be obtained from the specific organ- or cell-source donor pig or from an identical (cloned) pig. (ii) They are easy to obtain in large numbers, negating the need for prolonged ex vivo expansion. (iii) They can be obtained from genetically-engineered pigs, and the genetic modification can be related to the therapeutic goal of the MSCs. We have reviewed our own studies on MSCs from genetically-engineered pigs, and summarize them here. We have successfully harvested and cultured MSCs from wild-type and genetically-engineered pig bone marrow and adipose tissue. We have identified several pig (p)MSC surface markers (positive for CD29, CD44, CD73, CD105, CD166, and negative for CD31, CD45), have demonstrated their proliferation and differentiation (into adipocytes, osteoblasts, and chondroblasts), and evaluated their antigenicity and immune suppressive effects on human peripheral blood mononuclear cells and CD4+T cells. They have identical or very similar characteristics to MSCs from other mammals. Genetically-modified pMSCs are significantly less immunogenic than wild-type pMSCs, and downregulate the human T cell response to pig antigens as efficiently as do human MSCs. We hypothesized that pMSCs can immunomodulate human T cells through induction of apoptosis or anergy, or cause T cell phenotype switching with induction of regulatory T cells, but we could find no evidence for these mechanisms. However, pMSCs upregulated the expression of CD69 on human CD4+ and CD8+ T cells, the relevance of which is currently under investigation. We conclude that MSCs from genetically-engineered pigs should continue to be investigated for their immunomodulatory (and regenerative and anti-inflammatory) effects in pig-to-nonhuman primate organ and cell transplantation models.
引用
收藏
页码:79 / 85
页数:6
相关论文
共 50 条
  • [1] The Potential Role of Genetically-Modified Pig Mesenchymal Stromal Cells in Xenotransplantation
    Li, Jiang
    Ezzelarab, Mohamed B.
    Ayares, David
    Cooper, David K. C.
    STEM CELL REVIEWS AND REPORTS, 2014, 10 (01) : 79 - 85
  • [2] Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses
    Ezzelarab, Mohamed
    Ezzelarab, Corin
    Wilhite, Tyler
    Kumar, Goutham
    Hara, Hidetaka
    Ayares, David
    Cooper, David K. C.
    XENOTRANSPLANTATION, 2011, 18 (03) : 183 - 195
  • [3] Human T cells upregulate CD69 after coculture with xenogeneic genetically-modified pig mesenchymal stromal cells
    Li, Jiang
    Andreyev, Oleg
    Chen, Man
    Marco, Michael
    Iwase, Hayato
    Long, Cassandra
    Ayares, David
    Shen, Zhongyang
    Cooper, David K. C.
    Ezzelarab, Mohamed B.
    CELLULAR IMMUNOLOGY, 2013, 285 (1-2) : 23 - 30
  • [4] Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation
    Ekser, Burcin
    Lin, Chih C.
    Long, Cassandra
    Echeverri, Gabriel J.
    Hara, Hidetaka
    Ezzelarab, Mohamed
    Bogdanov, Vladimir Y.
    Stolz, Donna B.
    Enjyoji, Keiichi
    Robson, Simon C.
    Ayares, David
    Dorling, Anthony
    Cooper, David K. C.
    Gridelli, Bruno
    TRANSPLANT INTERNATIONAL, 2012, 25 (08) : 882 - 896
  • [5] Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties
    Kumar, Goutham
    Hara, Hidetaka
    Long, Cassandra
    Shaikh, Humza
    Ayares, David
    Cooper, David K. C.
    Ezzelarab, Mohamed
    CYTOTHERAPY, 2012, 14 (04) : 494 - 504
  • [6] An in vitro model of pig liver xenotransplantation-pig complement is associated with reduced lysis of wild-type and genetically modified pig cells
    Hara, Hidetaka
    Campanile, Nathalie
    Tai, Hao-Chih
    Long, Cassandra
    Ekser, Burcin
    Yeh, Peter
    Welchons, Dan
    Ezzelarab, Mohamed
    Ayares, David
    Cooper, David K. C.
    XENOTRANSPLANTATION, 2010, 17 (05) : 370 - 378
  • [7] Potential roles of mesenchymal stromal cells in islet allo- and xenotransplantation for type 1 diabetes mellitus
    Qu, Zepeng
    Lou, Qi
    Cooper, David K. C.
    Pu, Zuhui
    Lu, Ying
    Chen, Jiao
    Ni, Yong
    Zhan, Yongqiang
    Chen, Jun
    Li, Zhenjie
    Zhan, Naiyang
    Zeng, Yi
    Tu, Ziwei
    Cao, Huayi
    Dai, Yifan
    Cai, Zhiming
    Mou, Lisha
    XENOTRANSPLANTATION, 2021, 28 (03)
  • [8] Genetically modified pigs as donors of cells, tissues, and organs for xenotransplantation
    Wolf, Eckhard
    Kemter, Elisabeth
    Klymiuk, Nikolai
    Reichart, Bruno
    ANIMAL FRONTIERS, 2019, 9 (03) : 13 - 20
  • [9] INDUCTION OF ANTITUMOR RESPONSES BY GENETICALLY MODIFIED MESENCHYMAL STROMAL CELLS OVEREXPRESSING FLAGELLIN
    Damasceno, P. F.
    Orge, I. D.
    Sampaio, G. A.
    Silva, D. N.
    Santos, I. P.
    Barreto, B. C.
    Meira, C. S.
    Soares, M. B.
    CYTOTHERAPY, 2024, 26 (06) : S207 - S207
  • [10] Xenotransplantation of Genetically Modified Neonatal Pig Islets Cures Diabetes in Baboons
    Hawthorne, Wayne J.
    Salvaris, Evelyn J.
    Chew, Yi Vee
    Burns, Heather
    Hawkes, Joanne
    Barlow, Helen
    Hu, Min
    Lew, Andrew M.
    Nottle, Mark B.
    O'Connell, Philip J.
    Cowan, Peter J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13